SCHEMBL267501

SCHEMBL267501

CC(O)CN(Cc1cccc(C(=O)Nc2sc3ccccc3c2C(=O)NN=Cc2cccc(F)c2)c1)CC(C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XBP1 P17861 3/20 0.45
SLC34A2 O95436 6/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 1/20 0.44
SLC34A1 Q06495 1/20 0.44
SLC34A3 Q8N130 1/20 0.44
SLC20A1 Q8WUM9 1/20 0.44
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
POLB P06746 2/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
GUSB P08236 1/20 0.37
MAPT P10636 2/20 0.37
OGG1 O15527 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267500 1.00 XBP1 (0.45) XBP1SLC34A2KMT2AMEN1SMN1; SMN2
SCHEMBL269804 0.93 OGG1 (0.45) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL269805 0.93 OGG1 (0.45) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL265236 0.89 SLC34A2 (0.39) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL265237 0.89 SLC34A2 (0.39) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL268262 0.89 NPC1 (0.42) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL268263 0.89 NPC1 (0.42) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL269187 0.87 MAPT (0.43) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL269186 0.87 MAPT (0.43) SLC34A2KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL274062 0.86 SLC34A2 (0.54) SLC34A2SMN1; SMN2LMNASLC34A1SLC34A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 XBP1 2612/4885SLC34A2 6/4885KMT2A 4564/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 XBP1 3109/4885SLC34A2 2/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.